NAMSA has acquired Munich-based CRI - The Clinical Research Institute GmbH, a full-service Contract Research Organization (CRO).

Formed in 2011, CRI provides the European MedTech market with complete clinical research solutions to accelerate scientific outcomes applying cutting-edge data solutions.

NAMSA is the world’s leading MedTech CRO offering global end-to-end development services including medical device testing, regulatory, marketing, reimbursement and quality consulting as well as clinical research services. NAMSA is a portfolio company of ARCHIMED, a healthcare-focused global private equity firm.

GLNS provided advice to the shareholder of CRI.